Skip to main content

Table 3 Number of small-intestinal lesions per subject by capsule endoscopy at baseline and after treatment

From: Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study

 

Baseline

Post-treatment

p value1

Irsogladine group

   

Number of mucosal breaks (mean ± SD)

0.3 ± 0.8

0.5 ± 0.7

NS

Number of reddened lesions (mean ± SD)

0.2 ± 0.4

0.4 ± 0.6

NS

Number of sites of bleeding (mean ± SD)

0.0 ± 0.0

0.2 ± 0.5

NS

Omeprazole group

   

Number of mucosal breaks (mean ± SD)

0.1 ± 0.3

1.9 ± 2.0

0.0002

Number of reddened lesions (mean ± SD)

0.6 ± 0.8

1.3 ± 1.7

NS

Number of sites of bleeding (mean ± SD)

0.1 ± 0.3

0.3 ± 0.4

NS

  1. 1P-values are baseline versus post-treatment within groups.